Today marks the European launch of PRIMA, the first and only treatment to be commercially available that restores functional central vision to patients with geographic atrophy caused by dry age-related macular degeneration, a leading cause of blindness. The first European commercial implant of PRIMA is expected soon.
Science Corp secures CE mark to launch PRIMA retinal implant
AI Judge changed title after evaluation, original title: "Science Corporation launches PRIMA retinal implant in Europe"
The device restores functional vision lost to dry AMD.
8995894139514.8K
Original post
Market Adoption
Early commercial implants are now possible in select EU sites
Country-level reimbursement talks and clinic activations are underway, with the first paid procedures anticipated shortly in Germany for qualifying patients screened by retinal specialists.
Open Question
US patients still wait for full regulatory clearance
While PRIMA holds FDA Breakthrough and Humanitarian Use Device designations, a Humanitarian Device Exemption review is still required before any commercial availability stateside.
Sentiment
Many users congratulated Science Corp on the CE Mark for its PRIMA retinal implant as a major achievement in restoring sight via neurotechnology, while one objected to the profit motive behind it.
Pos
90.0%
Neg
10.0%
31 comments with sentiment.
Cluster Engagement
Digg Deeper
No Digg Deeper questions have been answered for this story yet.
Related links
Read more: https://science.xyz/news/ce-mark/